AAT Wound Care is a Veteran-Owned Small Business dedicated to transforming lives through innovative, cutting-edge solutions in wound care.
AAT Wound Care is a Veteran-Owned Small Business dedicated to transforming lives through innovative, cutting-edge solutions in wound care.
AAT Advanced Wound Care is a Veteran-Owned Small Business (VOSB)
open
AAT Wound Care is a Veteran-Owned Small Business dedicated to transforming lives through innovative, cutting-edge solutions in wound care.
AAT Wound Care is a Veteran-Owned Small Business dedicated to transforming lives through innovative, cutting-edge solutions in wound care.
AAT Advanced Wound Care is a Veteran-Owned Small Business (VOSB)
logo close menu

Our Mission

AAT Wound Care is a leading provider of wound care technologies. Our mission is to improve patients' lives by providing advanced wound care products.

Clinically
Tested

The bioactive allograft has proven to be highly effective, adaptable, and easy to use. With peer-reviewed literature from multiple publications, the allograft demonstrates real-world efficacy for wound care.1

Regenerative Capabilities

The allograft harnesses the regenerative power of the human amniotic membrane, providing unparalleled effectiveness in advanced wound care, boasting unique anti-inflammatory, anti-scarring, anti-microbial, and immunomodulatory bioactive healing properties.

Unparalleled
Patient Outcomes

The allograft is effective for a wide variety of medical fields, allowing clinicians to deliver exceptional patient care. Clinical wound care applications include diabetic, venous stasis, pressure, deep dermal ulcers and burns.

Dermacyte Matrix:A Cutting Edge Approach for Advanced Wound Care

Dermacyte® Amniotic Membrane Matrix (Dermacyte Matrix) is a human amniotic membrane allograft with a preserved epithelial basement membrane and compact fibroblast layer.

Our product is a commercially available extracellular tissue product and is intended for use as a protective covering for partial and full thickness wounds and surgical sites.

Based on proprietary advancements in amniotic tissue processing, Dermacyte Matrix is created from amniotic tissue that undergoes rigorous screening and is produced under the highest quality standards.

shutterstock_342696572 6
shutterstock_342696572 1
shutterstock_342696572 2
shutterstock_342696572 3
shutterstock_342696572 4
shutterstock_342696572 5

Unparalleled benefits

Protection

Protection

Acts as a protective barrier to cover wounds and soft tissue.
Versatility

Versatility

Allows for ease of use and applicability across various clinical settings.
Clinically Tested

Clinically Tested

Peer reviewed in multiple applications.1
Storage Efficiency

Storage Efficiency

Stable and uncomplicated storage.
image 16 (3)
Dermacyte Matrix Professional Brochure Download
Our findings indicate that AMM is an effective intervention for resolving diabetic and venous leg ulcers that fail to respond to conventional treatments.
Ditmars FS, Kay KE, Broderick TC, Fagg WS. Amniotic Membrane Resolves Treatment-Resistant Chronic Wounds: Evidence from a Multi-Center Retrospective Study.2

A recent multicenter study has demonstrated encouraging effectiveness and safety 
of Merakris Therapeutics’ Dermacyte® Amniotic Wound Care Matrix in treating hard-to-heal diabetic and venous leg ulcers (VLUs). Wounds with an average size of 20 cm2 showed a significant reduction in volume after a single application and a 50% reduction in wound size was observed after approximately two applications of Dermacyte Matrix, the study reported.

Ditmars FS, Kay KE, Broderick TC, Fagg WS. Amniotic Membrane Resolves Treatment-Resistant Chronic Wounds: Evidence from a Multi-Center Retrospective Study.2

Why is wound care essential?

  • Globally, 50 million (9M in US) people suffer from chronic wounds.
  • Chronic wounds impact the quality of life of nearly 2.5% of the total population of the United States.
  • Given the aging population, the continued threat of diabetes and obesity worldwide, and the persistent problem of infection, it is expected that chronic wounds will continue to be a substantial clinical, social, and economic challenge.4

Dermacyte Matrix is regulated by the U.S. Food and Drug Administration (FDA) as a minimally manipulated human allograft tissue under its Human Cells, Tissues, and Tissue-Based Products (HCT/P) guidelines, subject to Section 361 of the Public Health Service Act and 21 CFR 1271.

Our products are the proven choice in the market

Practical Considerations for the Use of Dermacyte AMM Brochure
Practical Considerations for the Use of Dermacyte AMM Brochure Download PDF
Dermacyte AMM Professional Brochure
Dermacyte AMM Professional Brochure Download PDF

Supporting better outcomes in wound care

Learn why leading healthcare professionals prefer to use the Dermacyte Matrix for advanced wound care

Learn why qualified patients request using the Dermacyte Matrix for advanced wound care.